A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain [3]

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 656-658

  Villano, J L ^a   Mauer, A M ^a   Vokes, E E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CASE REPORT; CLINICAL FEATURE; FEMALE; HOSPICE CARE; HUMAN; HUMAN TISSUE; LETTER; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BRAIN TUMOR; DISEASE FREE SURVIVAL; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; QUINAZOLINES; TREATMENT OUTCOME;

EID: 0037819319     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg151     Document Type: Letter

References (5)

1. Vokes EE, Charoentum C, Gordon GS et al. Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer. Clin Lung Cancer 2002; 3: 265-270.
2. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-1914.
3. Heimberger AB, Archer GE, McLendon RE et al. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa), is active against EGFR-overexpressing intracranial tumors. In: Proceedings of the 11th NCI·EORTC·AACR Symposium on New Drugs in Cancer Therapy, Amsterdam. Clin Cancer Res 2000; 6 (Suppl): (Abstr 380).
4. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
5. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.